Abstracts tagged "Late-Breaking 2016"

Abstract Number: 18L • 2016 ACR/ARHP Annual Meeting
Primary CNS Vaculitis Vs Neurosarcoidosis: Can We Predict the Diagnosis with MRI?
Didem Saygin¹, Priya Sundaram-Simonelli², Leonard H. Calabrese³, Elisabeth Ray⁴, William Messner⁵, Stephen Jones², Jinny Tavee⁶ and Rula A Hajj-Ali⁷, ¹Cleveland Clinic, Cleveland, OH, ²Neuroradiology, Cleveland Clinic, Cleveland, OH, ³Rheumatic & Immunologic Disease, Cleveland Clinic, Cleveland, OH, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH, ⁵Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ⁶Neuromuscular diseases, Cleveland Clinic, Cleveland, OH, ⁷Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH

Background/Purpose: Neurosarcoidosis and primary angiitis of central nervous system (PACNS) are inflammatory diseases affecting central nervous system, with overlapping clinical and pathological characteristics. Differentiating between…
Abstract Number: 3L • 2016 ACR/ARHP Annual Meeting
Comparative Cardiovascular Safety of Tocilizumab Vs Etanercept in Rheumatoid Arthritis: Results of a Randomized, Parallel-Group, Multicenter, Noninferiority, Phase 4 Clinical Trial
Jon T. Giles¹, Naveed Sattar², Sherine E. Gabriel³, Paul M. Ridker⁴, Steffen Gay⁵, Charles Warne⁶, David Musselman⁷, Laura Brockwell⁶, Emma Shittu⁶, Micki Klearman⁷ and Thomas Fleming⁸, ¹Columbia University, College of Physicians and Surgeons, New York, NY, ²Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ³Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Center for Cardiovascular Disease Prevention, Harvard Medical School, Boston, MA, ⁵University Hospital Zurich, Department of Rheumatology, Zurich, Switzerland, ⁶Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁷Genentech, South San Francisco, CA, ⁸University of Washington, Department of Biostatistics, Seattle, WA
Background/Purpose: Treatment of rheumatoid arthritis (RA) with tocilizumab (TCZ), a humanized monoclonal antibody directed against the IL-6 receptor, is associated with clinical efficacy and marked…
Abstract Number: 19L • 2016 ACR/ARHP Annual Meeting
Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway
Guro Løvik Goll^1,2, Inge C Olsen³, Kristin K Jorgensen⁴, Merete Lorentzen⁵, Nils Bolstad⁶, Espen A. Haavardsholm⁷, Knut EA Lundin⁸, Cato Mork⁹, Jorgen Jahnsen⁴, Tore K Kvien³ and the NOR-SWITCH study group, ¹Dept of Rheumatoogy, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumathology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept of Gastroenterology, Akershus University Hospital, Lorenskog, Norway, ⁵Dept of Dermatology, Rikshospitalet, Oslo, Norway, ⁶Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, ⁷Diakonhjemmet Hospital, Oslo, Norway, ⁸Dept of gastroenterology, Rikshospitalet, Oslo, Norway, ⁹Dept of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: TNF-inhibitors (TNFi) have improved treatment of spondyloarthritis (SpA), rheumatoid arthritis (RA), psoriatic arthritis (PsA), Crohn’s disease (CD), ulcerative colitis (UC), and chronic plaque…
Abstract Number: 4L • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety Results of Guselkumab, an Anti-IL23 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis over 24 Weeks: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
Atul A. Deodhar¹, Alice B Gottlieb², Wolf-Henning Boehncke³, Bin Dong⁴, Yuhua Wang⁴, William Barchuk⁵, Xie Xu⁵ and Elizabeth C. Hsia⁴, ¹Oregon Health & Science University, Portland, OR, ²Department of Dermatology, New York Medical College, Valhalla, NY, ³Department of Dermatology,, Geneva University Hospital, Geneva, Switzerland, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC, San Diego, CA
Background/Purpose: To evaluate the efficacy, safety, and tolerability of guselkumab (GUS), a fully human monoclonal antibody against the p19 subunit of IL-23, in patients (pts)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.